BDNF Levels in Cancer Patients Receiving Chemotherapy

NCT ID: NCT07019324

Last Updated: 2025-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-17

Study Completion Date

2026-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cognitive impairment following chemotherapy is defined as chemotherapy-induced cognitive impairment (CCIID). CCIID, which significantly reduces the quality of life of cancer patients receiving chemotherapy, develops as a result of neurotoxicity. It is stated that 75% of patients receiving chemotherapy have cognitive changes. In addition, 35% of patients complain of various cognitive impairments (hearing, perception, decision-making, etc.) for a few months after chemotherapy ends. This situation makes life conditions very difficult for patients who are already experiencing a very difficult disease and treatment process.

Brain-Derived Neurotrophic Factor (BDNF) is an extracellular signaling protein known for its dominant role in the development of the nervous system, such as neurogenesis, neuroprotection, neurodegeneration, synaptic plasticity, and resistance to neuronal stress. This protein has opposing effects with its mature form, pro-BDNF protein, and pro-BDNF/BDNF ratios affect neuronal health. Although a number of factors have been identified that are responsible for the deterioration of the cognitive levels of patients receiving chemotherapy, the role of BDNF and pro-BDNF levels in cognitive functions in cancer patients receiving chemotherapy is unknown. In light of this information, the aim of our study is to reveal the effects of chemotherapy-induced cognitive impairment (CIID) on pro-BDNF/BDNF levels and to evaluate the cognitive effects. In line with this aim, patients who apply to Çanakkale Onsekiz Mart University, Faculty of Medicine, Department of Oncology, Polyclinic and Chemotherapy Unit and who have not yet received their first chemotherapy will be included in the study. Before the first chemotherapy, during routine follow-ups in the 3rd month of chemotherapy and in the 6th month in Aydın, 1 extra tube of blood will be taken and BDNF levels will be examined. At the same time, the Montreal Cognitive Assessment (MoCA) test will be applied to the patients to evaluate their cognitive functions. Thus, serum BNDF, proBDNF levels will be determined and the BDNF/proBDNF ratio will be revealed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detection of chemotherapy-induced cognitive impairment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

BDNF Cognitive Functions Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cancer definations and decided the chemotherapy treatment

Exclusion Criteria

* Having other disease whixh effected cognitive function
* Brain cancers
* Brain metastasis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cemre Aydeğer

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cemre Aydeğer

Çanakkale Onsekiz Mart University

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Çanakkale Onsekiz Mart University

Çanakkale, Merkez, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TKB-2025-5052

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

TKB-2025-5052

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Multicentre Clinical Study
NCT07062666 NOT_YET_RECRUITING
Predictors of Cognitive Outcomes in Geriatric Depression
NCT05273996 ACTIVE_NOT_RECRUITING PHASE4